Amanote Research
Register
Sign In
Figure 2: Rosiglitazone Administration Accelerated Wound Closure in Db/Db Diabetic Mice.
doi 10.7717/peerj.7815/fig-2
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
PeerJ
Related search
Supplemental Information 2: Rosiglitazone Administration Accelerated Wound Closure in Db/Db Diabetic Mice
Figure 3: Rosiglitazone Administration Increased Wound Angiogenesis in Db/Db Diabetic Mice.
Supplemental Information 3: Rosiglitazone Administration Increased Wound Angiogenesis in Db/Db Diabetic Mice
Figure 4: Rosiglitazone Administration Improved BM-EPC Function in Db/Db Diabetic Mice.
Supplemental Information 4: Rosiglitazone Administration Improved BM-EPC Function in Db/Db Diabetic Mice
Rosiglitazone Accelerates Wound Healing by Improving Endothelial Precursor Cell Function and Angiogenesis in Db/Db Mice
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
Figure 5: Rosiglitazone Administration Increases the Levels of VEGF and SDF-1α Protein and Improved Insulin Resistant in Db/Db Mice.
MicroRNA-29b Inhibits Diabetic Nephropathy in Db/Db Mice
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Figure 1: Illustration of Experimental Schedule and Establishment of Db/Db Diabetic Mice Model.
